gutflix
GI learning, personalised

Summary

MIRIKIZUMAB DEMONSTRATES RAPID AND SUSTAINED IMPROVEMENTS IN BOWEL URGENCY MEASURES AND CLINICAL MEASURES IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: 28-WEEK RESULTS FROM THE PHASE 3B LUCENT-URGE TRIAL

Tian Tian

UEG Week Berlin 2025 Poster

IBD

October 7, 2025

LUCENT-URGE, a 28-week open-label study of mirikizumab in 172 adults with moderately-to-severely active ulcerative colitis and bowel urgency, demonstrated improvements in urgency severity, frequency, and stool deferral time alongside clinical and endoscopic outcomes.

KEY POINTS

- At week 28, mean urgency severity score improved by 3.6 points and urgency frequency decreased by 3.8 times per day from baseline, with 29.7% of patients achieving stool deferral time of 15 minutes or greater compared to 4.1% at baseline
- Clinical remission was achieved by 36.1% of patients and endoscopic remission by 44.2% at week 28, while 58.1% achieved clinically meaningful improvement in urgency score (reduction of 3 or more points)
- Half of patients achieved both clinical response and clinically meaningful urgency improvement at week 28, though only 16.3% achieved the combined endpoint of clinical remission and urgency remission
- The safety profile was consistent with previous mirikizumab studies, with no deaths reported and ulcerative colitis exacerbation and upper respiratory tract infection each occurring in 5.2% of patients
- This material is most relevant for gastroenterologists managing patients with moderate-to-severe ulcerative colitis who experience significant bowel urgency

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/1d4bee8c-a813-11f0-8f37-0242ac140006

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.